Full metadata record
DC FieldValueLanguage
dc.creatorRodriguez-Otero, P. (Paula)-
dc.creatorMateos, M.V. (María Victoria)-
dc.creatorMartínez-López, J. (Joaquín)-
dc.creatorHernandez, M.T. (Miguel Teodoro)-
dc.creatorOcio, E.M. (Enrique M.)-
dc.creatorRosiñol, L. (Laura)-
dc.creatorMartínez, R. (Rafael)-
dc.creatorTeruel, A.I. (Ana Isabel)-
dc.creatorGutierrez, N.C. (Norma C.)-
dc.creatorBargay, J. (Joan)-
dc.creatorBengoechea, E. (Enrique)-
dc.creatorGonzalez, Y. (Yolanda)-
dc.creatorPérez-de-Oteyza, J. (Jaime)-
dc.creatorGironella, M. (Mercedes)-
dc.creatorNuñez-Cordoba, J.M. (Jorge M.)-
dc.creatorEncinas, C. (Cristina)-
dc.creatorMartin, J. (Jesus)-
dc.creatorCabrera, C. (Carmen)-
dc.creatorPalomera, L. (Luis)-
dc.creatorArriba, F. (Felipe) de-
dc.creatorCedena, M.T. (María Teresa)-
dc.creatorPuig, N. (Noemí)-
dc.creatorOriol, A. (Albert)-
dc.creatorPaiva, B. (Bruno)-
dc.creatorBladé, J. (Joan)-
dc.creatorLahuerta, J.J. (Juan José)-
dc.creatorSan-Miguel, J.F. (Jesús F.)-
dc.identifier.citationRodríguez-Otero, P. (Paula); Mateos, M. V.; Martinez-Lopez, J.; et al. "Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature". Blood Cancer Journal. 9 (4), 2019, 36es
dc.description.abstractDisease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) >= 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb >= 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.-
dc.description.sponsorshipThis study was supported by the Centro de Investigación Biomédica en Red —Área de Oncología— del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369 and CB16/12/00377), Instituto de Salud Carlos III / Subdirección General de Investigación Sanitaria (FIS no. PS09/01897/01370, PI12/01761, PI12/02311,PI13/01469, PI14/01867, G03/136, CD13/00340), Asociación Española Contra el Cáncer (GCB120981SAN) and the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT).-
dc.titlePredicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature-
dc.description.noteThis article is licensed under a Creative Commons Attribution 4.0 International License (CCBY)-

Files in This Item:
359.1 kB
Adobe PDF

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.